scholarly journals Randomness of Möbius coefficients and Brownian motion: growth of the Mertens function and the Riemann hypothesis

2021 ◽  
Vol 2021 (11) ◽  
pp. 113106
Author(s):  
Giuseppe Mussardo ◽  
André LeClair

Abstract The validity of the Riemann hypothesis (RH) on the location of the non-trivial zeros of the Riemann ζ-function is directly related to the growth of the Mertens function M ( x ) = ∑ k = 1 x μ ( k ) , where μ(k) is the Möbius coefficient of the integer k; the RH is indeed true if the Mertens function goes asymptotically as M(x) ∼ x 1/2+ϵ , where ϵ is an arbitrary strictly positive quantity. We argue that this behavior can be established on the basis of a new probabilistic approach based on the global properties of the Mertens function, namely, based on reorganizing globally in distinct blocks the terms of its series. With this aim, we focus attention on the square-free numbers and we derive a series of probabilistic results concerning the prime number distribution along the series of square-free numbers, the average number of prime divisors, the Erdős–Kac theorem for square-free numbers, etc. These results point to the conclusion that the Mertens function is subject to a normal distribution as much as any other random walk. We also present an argument in favor of the thesis that the validity of the RH also implies the validity of the generalized RH for the Dirichlet L-functions. Next we study the local properties of the Mertens function, i.e. its variation induced by each Möbius coefficient restricted to the square-free numbers. Motivated by the natural curiosity to see how closely to a purely random walk any sub-sequence is extracted by the sequence of the Möbius coefficients for the square-free numbers, we perform a massive statistical analysis on these coefficients, applying to them a series of randomness tests of increasing precision and complexity; together with several frequency tests within a block, the list of our tests includes those for the longest run of ones in a block, the binary matrix rank test, the discrete Fourier transform test, the non-overlapping template matching test, the entropy test, the cumulative sum test, the random excursion tests, etc, for a total of 18 different tests. The successful outputs of all these tests (each of them with a level of confidence of 99% that all the sub-sequences analyzed are indeed random) can be seen as impressive ‘experimental’ confirmations of the Brownian nature of the restricted Möbius coefficients and the probabilistic normal law distribution of the Mertens function analytically established earlier. In view of the theoretical probabilistic argument and the large battery of statistical tests, we can conclude that while a violation of the RH is strictly speaking not impossible, it is however extremely improbable.

Author(s):  
Willemieke P M Dijksterhuis ◽  
Marianne C Kalff ◽  
Anna D Wagner ◽  
Rob H A Verhoeven ◽  
Valery E P P Lemmens ◽  
...  

Abstract Background Biological sex and gender have been reported to impact incidence and overall survival (OS) of curatively treated gastroesophageal cancer. The aim of this study was to compare palliative treatment allocation and OS between women and men with advanced gastroesophageal cancer. Methods Patients with an unresectable (cT4b) or metastatic (cM1) esophageal (including cardia) adenocarcinoma (EAC) or squamous cell carcinoma (ESCC), or gastric adenocarcinoma (GAC) diagnosed in 2015-2018 were identified in the Netherlands Cancer Registry. Treatment allocation was compared using chi-squared tests and multivariable logistic regression analyses, and OS using the Kaplan-Meier method with log-rank test and Cox proportional hazard analysis. All statistical tests were 2-sided. Results Of patients with EAC (n = 3,077), ESCC (n = 794) and GAC (n = 1,836), 18.0%, 39.4% and 39.1% were women, respectively. Women received less often systemic treatment compared to men in EAC (42.7% vs. 47.4%, P = 0.045) and GAC (33.8% vs. 38.8%, P = 0.03), but not in ESCC (33.2% vs. 39.5%, P = 0.07). Women had a lower probability of receiving systemic treatment in GAC in multivariable analyses (odds ratio [OR] = 0.79, 95% confidence interval [CI] = 0.62-1.00), but not in EAC (OR = 0.86, 95%CI = 0.69-1.06) and ESCC (OR = 0.81, 95%CI = 0.57-1.14). Median OS was lower in women with EAC (4.4 vs. 5.2 months, P = 0.04), but did not differ after adjustment for patient and tumor characteristics and systemic treatment administration. Conclusion We observed statistically significant and clinically relevant gender differences in systemic treatment administration and OS in advanced gastroesophageal cancer. Causes of these disparities may be sex-based, i.e. related to tumor biology, as well as gender-based, e.g. related to differences in treatment choices.


Author(s):  
Muhammad Saputra ◽  
Candra Kusuma Negara ◽  
Anna Martiana Afida ◽  
Henny Puspasari ◽  
Akhmad Murjani

Introduction: Stroke risk factors are related to the circumstances of a person's health status, namely hypercholesterolemia (excess cholesterol levels) and hypertension (high blood pressure).Methods: A correlative descriptive analytic observational study using cross sectional approach. The number of samples taken is as many as 62 people using the Slovinformula..Statistical analysis uses Sperman Rank Test and Linear regression test.Results: The results of this study indicate that the total cholesterol level of patients from 62 samples found that normal cholesterol levels amounted to 29 people (46.8%) consisting of 12 people (19.4%) with SH and 17 people ( 27.4%) with SNH and high cholesterol levels totaling 33 people (53.2%) divided into 7 people (11.3%) with SH and 26 people (42%) with SNH. There is a significant correlation between blood cholesterol levels with stroke incidence in statistical tests with p value 0,004 (p<0,05), there is a significant correlation between hypertension and stroke events withp value 0,031(p<0,05)there is no significant correlation between blood cholesterol levels and hypertension in statistical tests withp value 0,129 (p>0,05) and by using Linear regression test obtained that the correlation between blood cholesterol levels with a value of mean value hypertension  0.453 and mean 0.994 so that the most dominant with the incidence of stroke was hypertension.Conclusions: Have nothing to do with hypertension, it can be concluded here that stroke is caused by hypertension. The Suggestion is hypertension’s not only caused by cholesterol levels but there are other triggers that cause it.


2014 ◽  
Vol 25 (6) ◽  
pp. 1499-1506 ◽  
Author(s):  
Tae Yoon Kim ◽  
Cheolyong Park ◽  
Seul Gee Kim ◽  
Min Seok Kim ◽  
Woo Jung Lee ◽  
...  

2016 ◽  
Vol 54 (5) ◽  
pp. 1352-1356 ◽  
Author(s):  
Alda Saldan ◽  
Gabriella Forner ◽  
Carlo Mengoli ◽  
Daniel Tinto ◽  
Loredana Fallico ◽  
...  

Human cytomegalovirus (CMV) infection is a major cause of congenital infection leading to birth defects and sensorineural anomalies, including deafness. Recently, cell-mediated immunity (CMI) in pregnant women has been shown to correlate with congenital CMV transmission. In this study, two interferon gamma release assays (IGRA), the CMV enzyme-linked immunosorbent spot (ELISPOT) and CMV QuantiFERON assays, detecting CMV-specific CMI were compared. These assays were performed for 80 CMV-infected (57 primarily and 23 nonprimarily) pregnant women and 115 controls, including 89 healthy CMV-seropositive pregnant women without active CMV infection, 15 CMV-seronegative pregnant women, and 11 seropositive or seronegative nonpregnant women. Statistical tests, including frequency distribution analysis, nonparametric Kruskal-Wallis equality-of-populations rank test, Wilcoxon rank sum test for equality on unmatched data, and lowess smoothing local regression, were employed to determine statistical differences between groups and correlation between the assays. The CMV ELISPOT and CMV QuantiFERON assay data were not normally distributed and did not display equal variance. The CMV ELISPOT but not CMV QuantiFERON assay displayed significant higher values for primarily CMV-infected women than for the healthy seropositive pregnant and nonpregnant groups (P= 0.0057 and 0.0379, respectively) and those with nonprimary infections (P= 0.0104). The lowess local regression model comparing the assays on an individual basis showed a value bandwidth of 0.8. Both assays were highly accurate in discriminating CMV-seronegative pregnant women. The CMV ELISPOT assay was more effective than CMV-QuantiFERON in differentiating primary from the nonprimary infections. A substantial degree of variability exists between CMV ELISPOT and CMV QuantiFERON assay results for CMV-seropositive pregnant women.


Sensors ◽  
2019 ◽  
Vol 19 (9) ◽  
pp. 2137 ◽  
Author(s):  
Soojeong Lee ◽  
Gangseong Lee ◽  
Gwanggil Jeon

Oscillometric blood pressure (BP) monitors currently estimate a single point but do not identify variations in response to physiological characteristics. In this paper, to analyze BP’s normality based on oscillometric measurements, we use statistical approaches including kurtosis, skewness, Kolmogorov-Smirnov, and correlation tests. Then, to mitigate uncertainties, we use a deep learning method to determine the confidence limits (CLs) of BP measurements based on their normality. The proposed deep learning regression model decreases the standard deviation of error (SDE) of the mean error and the mean absolute error and reduces the uncertainties of the CLs and SDEs of the proposed technique. We validate the normality of the distribution of the BP estimation which fits the standard normal distribution very well. We use a rank test in the deep learning technique to demonstrate the independence of the artificial systolic BP and diastolic BP estimations. We perform statistical tests to verify the normality of the BP measurements for individual subjects. The proposed methodology provides accurate BP estimations and reduces the uncertainties associated with the CLs and SDEs using the deep learning algorithm.


2020 ◽  
Vol 19 ◽  
pp. 153303382096558
Author(s):  
Wenbo Guo ◽  
Song Chen ◽  
Zhiqiang Wu ◽  
Wenquan Zhuang ◽  
Jianyong Yang

Objective: This study aimed to explore the efficacy and safety of using transarterial chemoembolization (TACE) combined with anlotinib in patients with unresectable hepatocellular carcinoma, compared with TACE alone. Methods: This was a single-center study, retrospectively recruited 82 unresectable HCC patients who received either TACE alone (TA group; n = 46) or TACE combined with anlotinib (TC group; n = 36) between Jan 2018 and Jan 2019. The primary outcomes were progression-free survival (PFS) and overall survival (OS). While the secondary outcomes were the objective response rate (ORR), the disease control rate (DCR), and main complications. Log-rank test and Kaplan–Meier method was used to calculate the survival difference. All statistical tests were 2-sided and P value <0.05 were taken as statistically significant. Results: Patients in TC group had a significant higher PFS than those in TA group (7.35 months vs. 5.54 months, p = 0.035). Although 3-month survival rate in the 2 groups was not statistically different (97.2% vs. 93.5%, p = 0.627), the survival rate at 6 months and 1 year were strongly higher in TC group (83.3% vs. 56.5%, p = 0.016; 66.7% vs. 19.6%, respectively, p < 0.05). Furthermore, there was a significantly higher ORR in TC group, while no statistical difference existed in DCR. Neither treatment-related mortality nor grade 4 adverse events (AEs) occurred. However, 2 patients in TC group had grade 3 AEs (one suffered with erythra, and the other with hand-foot-skin reaction), which disappeared after prompt treatment. Conclusion: TACE combined with anlotinib is safe and may improve outcomes for unresectable HCC patients comparing with TACE alone. Randomized controlled trials are warranted to further evaluate treatment effects of anlotinib in HCC.


2008 ◽  
Vol 28 (2) ◽  
pp. 423-446 ◽  
Author(s):  
Y. GUIVARC’H ◽  
EMILE LE PAGE

AbstractWe consider a random walk on the affine group of the real line, we denote by P the corresponding Markov operator on $\mathbb {R}$, and we study the Birkhoff sums associated with its trajectories. We show that, depending on the parameters of the random walk, the normalized Birkhoff sums converge in law to a stable law of exponent α∈ ]0,2[ or to a normal law. The corresponding analysis is based on the spectral properties of two families of associated transfer operators Pt,Tt. The operator Pt is a Fourier operator and is considered here as a perturbation of the Markov operator P=P0 of the random walk. The operator Tt is related to Pt by a symmetry of Heisenberg type and is also considered as a perturbation of the Markov operator T0=T. We prove that these operators have an isolated dominant eigenvalue which has an asymptotic expansion involving fractional powers of t. The parameters of this expansion have simple expressions in terms of tails and moments of the stationary measures of P and T.


2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 536-536
Author(s):  
Michio Nakamura ◽  
Satoshi Yuki ◽  
Masayoshi Dazai ◽  
Yoshimitsu Kobayashi ◽  
Takashi Kato ◽  
...  

536 Background: Mutations of the KRAS gene were identified as a predictive marker in mCRC for anti-EGFR antibody. Previously reported data suggest that the longer overall survival (OS) observed with bevacizumab (BV) treatment in mCRC is independent of alterations in the KRAS status. We analized efficacy of BV combined irinotecan and S-1 (IRIS/Bev) in mCRC relative to KRAS status. Methods: In the retrospective analysis (n=53) of patients who participated in the Phase II trial of IRIS/Bev, additional statistical analyses were done with data from KRAS mutational analyses. In this trial, eligible patients had to have mCRC with a confirmed diagnosis of adenocarcinoma, an age of >20 years, and no history of prior chemotherapy. S-1 40-60 mg twice daily p.o. was given on days 1-14 and irinotecan 100 mg/m2 and bevacizumab 5 mg/kg i.v. were given on days 1 and 15 of a 28-day cycle. The Response Evaluation in Solid Tumors (RECIST) criteria version 1.0 was used to assess tumor response. The Kaplan–Meier method was used to determine Progression-free survival (PFS) and OS. Log-rank test was used to compare with mutant or wild-type KRASin terms of PFS and OS. All statistical tests were performed using SPSS. Results: The target number of 53 patients was enrolled as of March 2009. KRAS status was assessed in 43 patients (wild = 27, mutant = 16). Response rate was 63.0% with wild-type and 68.8% with mutant-type KRAS, that was not significant (p=0.752). The median Progression-free survival was 17.1 months with wild-type and 22.7 months with mutant-type KRAS, that was not significant (p=0.531). And median OS was 49.0 months with wild-type and 38.0 months with mutant-type KRAS, that was not significant(p=0.906) as well. Conclusions: IRIS/Bev provides clinical benefit in patients with mCRC expressing either mutant or wild-type KRAS. Randomized control trial comparing this regimen with oxaliplatin containing regimen(XELOX or mFOLFOX6 plus bevacizumab: TRICOLORE study) is already started. Comparison of the efficacy of KRAS status is also planned in this study. Clinical trial information: NCT00569790.


Sign in / Sign up

Export Citation Format

Share Document